There are 3161 resources available
1135P - Multi-modal and longitudinal characterization of the tumor and immune microenvironment of Merkel cell carcinoma
Presenter: Maximilian Haist
Session: Poster session 04
1136P - Cosibelimab in advanced cutaneous squamous cell carcinoma (CSCC): Longer-term efficacy and safety results from pivotal study
Presenter: Eva Muñoz-Couselo
Session: Poster session 04
1137P - Efficacy of LNS8801 in melanoma patients with prior immune-related adverse events from immune-checkpoint inhibitors
Presenter: Justine Cohen
Session: Poster session 04
1138P - A prospective study of patients with immune checkpoint inhibitor-induced hepatitis: Management outcome and association with liver injury subtype, immune infiltration, and clinical parameters
Presenter: Rikke Holmstroem
Session: Poster session 04
1139TiP - IDE196 (darovasertib) in combination with crizotinib versus investigator’s choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma
Presenter: Marcus Butler
Session: Poster session 04
1140TiP - Safe stop IPI-NIVO trial: Early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab
Presenter: Joséphine Janssen
Session: Poster session 04
1210P - Neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy and adjuvant pembro or pbo for early stage NSCLC: Subgroup analyses of the phase III KEYNOTE-671 study
Presenter: Marina Garassino
Session: Poster session 04
1211P - IMpower010: ctDNA status and 5y DFS follow up in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)
Presenter: Heather Wakelee
Session: Poster session 04
1212P - IMpower010: Characterisation of patients (pts) with stage II-IIIA PD-L1 TC≥50% NSCLC who were disease-free at 5 years (5yDF) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after resection and adjuvant (adj) chemotherapy (chemo)
Presenter: Enriqueta Felip
Session: Poster session 04
1213P - Neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS vs. neoadjuvant placebo (PBO) plus CT with adjuvant PBO in resectable non-small cell lung cancer (NSCLC): patient-reported outcomes (PRO) in the RATIONALE-315 trial
Presenter: Federico Cappuzzo
Session: Poster session 04